Here’s how investors should make decisions about buying, holding or selling Clovis Oncology, Inc. (NASDAQ:CLVS) stock. On Thursday, shares of Clovis Oncology, Inc. (NASDAQ:CLVS) closed lower after an active session. The shares dropped -0.12 points or -0.6 percent at $19.87 with a heavy trade volume of 4.365 million shares. After opening the session at $19.54, the shares went as high as $20.34 and as low as $18.51, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $1.05 billion and now has 52.68 million shares outstanding. Clovis Oncology, Inc. (CLVS) stock has gained 38.95 percent of market value in 21 trading days.
CLVS stock has a trailing 3-year beta of 2.04, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$2.97 a share in the trailing twelve months. The stock’s value has fallen -70.78 percent year to date (YTD) against a decline of -65.56 percent in 12 month’s time. The company’s shares still trade -71.21 percent away from its 1-year high of $69.02 and 72.78 percent up from 52-week low of $11.50. The average consensus rating on the company is 2.3, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.
Clovis Oncology, Inc. (CLVS) will probably climb 19.28 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $40-month high price target. This represents a whopping 101.31 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $21.5, which represents a return potential of 8.2 percent when compared to the closing price of the stock of $19.87 on Thursday, December 06. The lowest price target for the stock is $16 — slightly more than -19.48 percent from CLVS’s current share price.
History has shown that shares in Clovis Oncology, Inc. have gone down on 15 different earnings reaction days and are predicted to add 0.04 percent when the company reports upcoming earnings. Investors will get their next glimpse of CLVS’s Q4 earnings on February 25. Analysts are forecasting revenue to climb 38.7 percent to $23.63M in the fiscal fourth quarter, while earnings are seen soaring by nearly -100 percent to $0 per share. It earned -$1.71 per share, worse than the -$1.6, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $22.76M, worse than the $30.11M analysts expected. Earnings are estimated to increase by 56.9 percent this year, 13.4 percent next year and continue to increase by 29.4 percent annually for the next 5 years.
Let’s take a look at some insider activity at Clovis Oncology, Inc. (NASDAQ:CLVS) and see the pattern. The earliest insider trade took place on 12/04/2018. Rolfe Lindsey parted with a total of 0.28 thousand shares of company at average share price of $21.23. The total for the sales was set at $6.03 thousand. After this transaction, the account balance stood at 14.16 thousand shares. The stock lost -6.41 percent since that insider sale. On 12/04/2018, Muehl Daniel W, sold 0.19 thousand shares at a price per share of $21.23. This removed 3.99 thousand shares from the insider’s fortune and the stock saw a -6.41 percent retreat in value since the news became public. This transaction left 5.66 thousand shares in the account.
On 12/04/2018, Ivers-Read Gillian C performed a sale transaction worth $5.31 thousand. This sale at $21.23 each has eliminated 0.25 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -6.41 percent decrease since the transaction was reported. The insider now is left with 186.15 thousand shares remaining in the account. Spickschen Thorlef, who performs the Director job, sold 4.5 thousand shares for $270.09 thousand. The disposal occurred on 04/09/2018 was priced at $60.02 per share. The share price plunged -66.89 percent since the reporting date. Spickschen Thorlef now left with a stake of 7.62 thousand CLVS stock worth $151.37 thousand after the insider selling.
The stock is currently hovering around the first support level of $18.81. Below this, the next support is placed in the zone of $17.74. Till the time, the CLVS stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 55.42 on daily chart, which may remain a cause for concern. If the price breaks below $17.74 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $20.64 mark may result into a pull-back move towards $21.4 level.
Further, it is sporting a 12.75 on the Price-to-Sales ratio. Compare this with the industry average P/S of 242.95. 79.8 percent is the gross profit margin for Clovis Oncology, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.